Organon will present eight [1] research abstracts regarding affordability, access, and biosimilar adoption at the ISPOR 2026 [2] conference.
This move signals a strategic focus on the economic viability of healthcare. By analyzing how patients access medicine, the company aims to address systemic barriers to care and the adoption of more affordable drug alternatives.
The research presented by the global healthcare company will span several therapeutic areas. These include women’s health, dermatology, neurology, and general medicines portfolios [1]. A primary focus of the upcoming presentations is to highlight contraception affordability and the role of biosimilar adoption in reducing costs for patients [1].
Biosimilars are highly similar versions of already approved biological medicines. Increasing their adoption is often seen as a way to lower the overall cost of treatment while maintaining efficacy. Organon intends to use the ISPOR 2026 [2] platform to share access-focused analyses that demonstrate the value of these medicines within the broader healthcare system [1].
The company, based in Jersey City, New Jersey, is utilizing the conference to showcase its commitment to value-based healthcare. The eight [1] abstracts will provide data-driven insights into how the company's portfolio affects patient outcomes and healthcare spending [1].
Organon continues to position itself as a leader in women's health by emphasizing the necessity of affordable contraceptive options. The company said the research is intended to highlight the intersection of clinical value and patient access [1].
“Organon will present eight research abstracts on affordability, access, and biosimilar adoption.”
The presentation of this research at ISPOR 2026 suggests that Organon is attempting to align its corporate value proposition with the global shift toward value-based pricing. By focusing on biosimilars and contraception affordability, the company is targeting high-growth, cost-sensitive sectors of the pharmaceutical market to improve patient reach and market penetration.
